Chemotherapy and skin reactions

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Fabbrocini, Gabriella ^a   Cameli, Norma ^b   Romano, Maria Concetta ^c   Mariano, Maria ^b   Panariello, Luigia ^a   Bianca, Dario ^a   Monfrecola, Giuseppe ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

^c ASL Roma B   (Italy)

Author keywords

Anti EGF; Chemotherapy; Follicular rash; Paronychia; Skin toxicity; Xerosis

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; LAPATINIB; PANITUMUMAB;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CLINICAL EXAMINATION; COLORECTAL CANCER; DRUG ERUPTION; DRY SKIN; ERYTHEMA; ESOPHAGUS CANCER; FEMALE; HAIR DISEASE; HODGKIN DISEASE; HUMAN; ITALY; KIDNEY CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAIL; NAIL DISEASE; NEURILEMOMA; NEUROENDOCRINE TUMOR; NONHODGKIN LYMPHOMA; OUTPATIENT DEPARTMENT; OVARY CANCER; PAPULE; PARONYCHIA; PRIORITY JOURNAL; PROSTATE CANCER; PUSTULE; SIDE EFFECT; SKIN CARE; SKIN MANIFESTATION; SKIN PRURITUS; STOMACH CANCER; THYROID CANCER; UTERUS CANCER; XEROSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84861443537     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-50     Document Type: Article

References (15)

1. Chemiotheraputic agents and the skin: an update. Noushin H, Haley N, Susan B, J Am Acad Dermatol 2008 58 545 570 10.1016/j.jaad.2008.01.001 18342708
2. Skin toxicities associated with epidermal growth factor receptor inhibitors. Tianhong L, Roman P, Targ Oncol 2009 4 107 119 10.1007/s11523-009- 0114-0
3. Classification and management of skin, hair and nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Galimont-Collen AFS, Vos LE, Lavrijsen APM, Ouwerkerkb J, Gelderblomb H, Eur J Cancer 2007 43 845 851 10.1016/j.ejca.2006.11.016 17289377
4. Do patients die from rashes from epidermal growth factor receptor inhibitors? A systematic review to help counsel patients about holding therapy. Jatoi A, Nguyen PL, Oncologist 2008 13 1201 1204 10.1634/theoncologist.2008-0149 18988655
5. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologists perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Wagner LI, Lacouture ME, Oncology (Williston Park) 2007 21 34 36
6. Common terminology criteria for adverse events (CTCAE) version 4.03. U. S. Department of Health and Human Services, 2010
7. The growing importance of skin toxicity in EGFR inhibitor therapy. Lacouture ME, Oncology (Williston Park) 2009 23 194 196
8. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Pérez-Soler R, Oncology (Williston Park) 2003 17 23 28
9. Capecitabine induced hyperpigmentation. Vasquez-Bayo C, Rodriguez-Bujaldon AL, Jimenez-Puya R, Galn-Gutierrez M, Moreno-Gimenez JC, Actas Dermosifiliogr 2007 98 491 493 10.1016/S0001-7310(07)70114-X 17669305
10. Candidate mechanisms for capecitabine related hand-foot syndrome. Milano G, Etlenne-Grimaldi MC, Marl M, Lasalle S, Formento JL, Francoual M, et al. Br J Clin Pharmacol 2008 66 188 95
11. Peculiar pattern of nail pigmentation following cyclophosphamide therapy. Dave S, Thappa DM, Dermatol Online J 2003 9 3 14 14996387
12. Unusual nail pigmentation following cyclophosphamide-containing chemotherapy regimen. Kumar S, Dixit R, Karmakar S, Paul S, Indian J Pharmacol August 42 4 243 244
13. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with Sorafenib. Vincenzi B, Santini D, Russo A, Addeo R, Giuliani F, Montella L, et al. The Oncologist 2010 15 85 92 10.1634/theoncologist.2009-0143 20051477
14. Sorafenib-induced premalignant and malignant skin lesions. Williams V, Cohen P, Stewart D, Int J Dermatol 2011 50 4 396 402 10.1111/j.1365-4632.2010. 04822.x 21413947
15. Hypertension and hand-foot skin reaction related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib. Jain L, Sissung TM, Danesi R, Kohn EC, Dahut WL, Kummar S, et al. J Exp Clin Cancer Res 2010 29 95 10.1186/1756-9966-29-95 20630084